Ironwood Pharmaceuticals (IRWD) Total Debt (2013 - 2026)

Ironwood Pharmaceuticals (IRWD) has 13 years of Total Debt data on file, last reported at $584.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 51.91% year-over-year to $584.9 million; the trailing twelve-month figure through Mar 2026 stood at $584.9 million (up 51.91% YoY), and the FY2025 full-year result was $584.7 million, up 51.86% from the prior year.
• Total Debt steadied at $584.9 million in Q1 2026, from $584.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $599.1 million in Q2 2023 to a low of $120.6 million in Q1 2022.
• A 5-year average of $473.2 million and a median of $499.6 million in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt slipped 29.06% in 2024 and jumped 51.91% in 2026, its largest moves.
• Tracing IRWD's Total Debt over 5 years: stood at $120.6 million in 2022, then soared by 314.29% to $499.6 million in 2023, then declined by 22.93% to $385.0 million in 2024, then surged by 51.86% to $584.7 million in 2025, then gained by 0.03% to $584.9 million in 2026.
• Business Quant data shows IRWD's Total Debt at $584.9 million in Q1 2026, $584.7 million in Q4 2025, and $584.5 million in Q3 2025.